As of 2025-08-09, the EV/EBITDA ratio of Acceleron Pharma Inc (XLRN) is -41.25. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Acceleron's latest enterprise value is 10,456.47 mil USD. Acceleron's TTM EBITDA according to its financial statements is -253.46 mil USD. Dividing these 2 quantities gives us the above Acceleron EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 9.4x - 13.0x | 12.1x |
| Forward P/E multiples | 12.4x - 18.7x | 13.0x |
| Fair Price | (46.31) - (48.91) | (47.11) |
| Upside | -125.9% - -127.4% | -126.4% |
| Date | EV/EBITDA |